Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:45 a.m. ET.

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Eli Lilly

Vertex Pharmaceuticals

The sky is the limit for CRISPR Therapeutics. Eli Lilly is a growth machine that will not stop anytime soon.

3 Unstoppable Stocks to Buy Hand Over Fist in April

CRISPR Therapeutics has a diverse pipeline of gene therapies and strategic partnerships, positioning it at the forefront of life science innovation. The approval of CASGEVY, the first CRISPR-based medicine, for transfusion-dependent β-thalassemia and sickle cell disease, signifies a significant milestone for the company. The company has upcoming catalysts, including updates on CASGEVY, the CTX112 program, CTX131, CTX211, CTX310, CTX320, and undisclosed targets, which could validate its technology and drive value creation.

Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans

Crispr stock is down for the fifth straight week as the top Cathie Wood's holding struggles amid dim expectations for its gene-editing drug.

Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why

Moderna

Bio-Techne

Last year was a tough one for biotech stocks. The Securities and Exchange Commission reported 41 bankruptcies following the Fed's interest rate hiking cycle, making it difficult to finance debt.

3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition

Medtronic

Pfizer

Investing in a variety of healthcare players could add a lot to your portfolio -- from dividends to growth. This offers you an opportunity to diversify and potentially score a big win over time.

3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000

Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available for CASGEVY in approved countries. Private insurers are showing interest in covering CASGEVY, providing further support for its commercial launch.

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

CRISPR Therapeutics AG (CRSP) reachead $71.08 at the closing of the latest trading day, reflecting a -0.74% change compared to its last close.

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Axsome Therapeutics

Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Novo Nordisk

Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for significant advances this year.

3 Biopharma Stocks Predicted to Soar in Q2 2024

CRISPR Therapeutics received important regulatory approvals last year. The company could make plenty of money on its lone marketed product.

Is It Too Late to Buy CRISPR Therapeutics Stock?

Amazon

AeroVironment

Even with the wider market rebound, Cathie Wood hasn't quite recaptured her initial investment allure. Her flagship fund, the ARK Innovation ETF (NYSEARCA: ARKK ), remains a full two-thirds below its 2021 highs.

The 3 Most Undervalued Cathie Wood Stocks to Buy in March 2024

Arrowhead Pharmaceuticals

Cytokinetics

Halozyme Therapeutics

Jazz Pharmaceuticals

SpringWorks Therapeutics Inc

Viking Therapeutics

While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

ZUG, Switzerland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the Company's annual general meeting to be held this year.

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Amylyx Pharmaceuticals

Investing in biotechnology (biotech) stocks is often thought of as being too risky for most investors. That's not necessarily the case.

The Top 3 Biotech Stocks to Buy in March 2024

Last month, the company's first treatment received clearance from European Union regulators, having previously been approved in the U.S. and the U.K. Its cash burn was lower than expected in the fourth quarter, and it made progress on new product development. The stock is still likely to experience significant volatility for the foreseeable future.

Here's Why CRISPR Therapeutics Stock Climbed 34% in February

ChatGPT stock predictions could be more than shots in the dark by AI. The processing and inferential power of artificial intelligence progresses seemingly exponentially every day.

ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential

CRISPR Therapeutics is launching its first medicine, which is bullish. It'll also be giving investors updates on a couple of important programs.

CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst

Biotech stocks have long been a speculative, albeit rewarding way to invest in the advancement of medical technology. This industry has a wide range of companies, from start-up firms that are researching their first treatment to pharmaceutical giants that are among the largest and most powerful companies in the world.

3 Biotech Stocks Bound to Blast Off By 2029

Amgen

CRISPR Therapeutics' recent major regulatory win could be the first of many. Axsome Therapeutics should ride the wave from its rich late-stage pipeline.

3 Biotech Stocks to Buy and Hold for the Next 10 Years

CRISPR Therapeutics AG NASDAQ: CRSP made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. NASDAQ: VRTX received the first-ever FDA approval for a gene-editing therapy for sickle-cell disease (SCD) called Casgevy on Dec 8, 2023. This FDA approval was a boon to the medical sector and notably for gene therapy focused biotechs like Intellia Therapeutics Inc. NASDAQ: NTLA and Beam Therapeutics Inc. NASDAQ: BEAM.

Is CRISPR Therapeutics the NVIDIA of gene editing?

CRISPR Therapeutics just wowed the market by launching its first drug. Caribou Biosciences is nowhere near an attempt at a launch.

Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR Therapeutics has experienced significant growth in the past five years, with its stock price soaring and then stabilizing around $80. The company has achieved regulatory approval for its CRISPR-based therapy for sickle cell disease and beta-thalassemia and has a diverse pipeline targeting various diseases. Investing in CRISPR Therapeutics requires risk tolerance and a long-term perspective, as the road to commercial success is complex and uncertain.

News for CRISPR Therapeutics Stock (CRSP)